GSK gives up on bigger stake in Nigerian unit; Astellas nabs FDA nod for transplant drug;


 @FiercePharma: Chinese police pick up AstraZeneca sales rep for questioning. AZN says no reason to think it's part of bribery probe. Report | Follow @FiercePharma

 @CarlyHFierce: Reuters says Roche may have to turn to an outsider for its chairman hunt. News | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) said it has abandoned a bid to increase its stake in its Nigerian unit after minority shareholders opposed the deal. Report

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Astellas Pharma won FDA approval for its once-daily drug to prevent transplant rejection, AstraGraf XL, a new formulation of the older product Prograf. Release

> A U.S. judge allowed a failure-to-warn suit against Boehringer Ingelheim to proceed, with plaintiff Mark Jackson alleging that the company didn't properly flag the bleeding risks associated with its anticoagulant Pradaxa. Report

> Forest Laboratories ($FRX) said it has settled another Bystolic patent fight, allowing generics maker Amerigen to launch its version three months ahead of the drug's U.S. patent expiration. Release

> Celesio said it has recruited Novartis ($NVS) executive Alexander Triebnigg to take over management of the Brazilian wholesaler Panpharma. Report

> As painkiller abuse continues to kill patients, pain doctors are asking more patients to take urine tests to show that they are taking the powerful drugs as prescribed. Report

> A former CVS pharmacist sued the company alleging that he was wrongfully dismissed, partly because he complained that staff cutbacks were increasing medication errors. Report

Medical Device News

 @FierceMedDev: Med tech VC investing remains sluggish, biotech surges. Report | Follow @FierceMedDev

 @MarkHFierce: Google is backing Dx company SynapDx in its new $15.4M funding round. Release (PDF) | Follow @MarkHFierce

 @DamianFierce: Mela's melanoma-finding device was hailed as a major advance on FDA approval, but docs remain wary. Story | Follow @DamianFierce

> Saladax draws another $8M from GE to market cancer tests. News

> Medtronic's auto-adjust insulin pump on cusp of FDA approval. More

> ResMed wages patent battle with Chinese medical device maker. Item

Biotech News

 @FierceBiotech: Popular this weekend - Report: Pfizer backs off Onyx bid as price gets too rich. Article | Follow @FierceBiotech

 @JohnCFierce:  Report: Big Pharma mounts secret attack against data transparency rule - (some companies will never learn). Report | Follow @JohnCFierce

 @RyanMFierce: Roche is still undecided about new chair. Art Levinson dismissed as "too radical." Reutersarticle | Follow @RyanMFierce

 @EmilyMFierce: New 3-D model of diabetes target could shape drug design. More | Follow @EmilyMFierce

> Does Roche need a biotech brain in the chairman's office? Story

> Isis Pharma fuels fervor for cardio drug with more midstage data. Report

> Biotech vets pick up $10M B round for startup Alcresta. News

CRO News

> ResearchDx expands to meet contract diagnostics demand. Report

> CROs large and small get serious about eClinical. More

> Aesica teams with QRxPharma for abuse-deterrence tech. Item

> CRO Solutions spins niche services into new biz. Story

> AstraZeneca picks Tufts for outsourcing-heavy neuro program. Article

> WuXi, PRA snag ex-Theorem CEO to head China JV. News

Biotech IT News

> J&J searching for European digital health entrepreneurs. Item

> Chinese CRO buys software to bridge gap to global clients. More

> Bioinformatics buy bolsters Life Technologies' diagnostics pact with Merck Serono. Story

> With pharma clientele, Big Data-mapping startup Ayasdi lands $30.6M financing. Article

And Finally... Low vitamin D levels in people over 55 are associated with increased disability, a study found. Report